Santen Pharmaceutical (OTCMKTS:SNPHY) Trading 11.9% Higher – Should You Buy?

Santen Pharmaceutical Co., Ltd. (OTCMKTS:SNPHY) shares shot up 11.9% during mid-day trading on Thursday . The company traded as high as $11.57 and last traded at $11.57. 252 shares were traded during trading, a decline of 98% from the average session volume of 15,812 shares. The stock had previously closed at $10.34.

Wall Street Analyst Weigh In

Separately, Zacks Research raised shares of Santen Pharmaceutical to a “hold” rating in a report on Monday, April 13th. One equities research analyst has rated the stock with a Hold rating, Based on data from MarketBeat, Santen Pharmaceutical has a consensus rating of “Hold”.

Santen Pharmaceutical Trading Up 1.6%

The company has a market capitalization of $3.78 billion and a PE ratio of 0.10. The stock has a fifty day moving average of $10.87 and a two-hundred day moving average of $10.69.

Santen Pharmaceutical Company Profile

Santen Pharmaceutical Co, Ltd. is a Japan‐based specialty pharmaceutical company focused exclusively on ophthalmology. Headquartered in Osaka, Santen engages in the research, development, manufacture and marketing of prescription and over‐the‐counter products for the diagnosis and treatment of eye diseases. Its core product portfolio includes therapies for glaucoma, dry eye, retinal disorders, uveitis and post‐operative care, as well as surgical equipment and diagnostic agents designed to support comprehensive eye care.

With roots tracing back to the late 19th century, Santen has grown from a domestic manufacturer to a global ophthalmic specialist.